دورية أكاديمية
The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
| العنوان: | The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience. |
|---|---|
| المؤلفون: | Dyakonova YY; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia., Bydanov OI; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.; Республиканский Republican Scientific and Practical Center for Pediatric Oncology, Hematology, and Immunology, Minsk, Republic of Belarus., Popov AM; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia., Olshanskaya YV; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia., Boichenko EG; СПбГУЗ «Children City Hospital №1, Saint-Petersburg, Russia., Aleynikova OV; Республиканский Republican Scientific and Practical Center for Pediatric Oncology, Hematology, and Immunology, Minsk, Republic of Belarus., Maschan MA; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia., Shelikhova LN; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia., Litvinov DV; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia., Khachatryan LA; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia., Ponomareva NI; Russian Children Clinical Hospital, Moscow, Russia., Fechina LG; Regional Children Clinical Hospital №1, Ekaterinburg, Russia., Novichkova GA; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia., Pashanov ED; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia., Karachunskiy AI; Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia. |
| المصدر: | Terapevticheskii arkhiv [Ter Arkh] 2018 Aug 17; Vol. 90 (7), pp. 38-50. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: ZAO 'Konsilium Medikum Country of Publication: Russia (Federation) NLM ID: 2984818R Publication Model: Print Cited Medium: Print ISSN: 0040-3660 (Print) Linking ISSN: 00403660 NLM ISO Abbreviation: Ter Arkh Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2018- > : Moskva : ZAO 'Konsilium Medikum' Original Publication: Moskva : Izdatelʹstvo Medit︠s︡ina |
| مواضيع طبية MeSH: | Antineoplastic Agents/*therapeutic use , Arabinonucleosides/*therapeutic use , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy , Prodrugs/*therapeutic use, Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Arabinonucleosides/adverse effects ; Arabinonucleosides/pharmacokinetics ; Clinical Trials as Topic ; Humans ; Injections, Intravenous ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/mortality ; Prodrugs/adverse effects ; Prodrugs/pharmacokinetics ; Progression-Free Survival ; Recurrence |
| مستخلص: | Aim: The analysis of experience of nelarabine use in refractory/relapsed T-cell acute lymphoblastic leukemia (T-ALL) depending on the immunophenotype and the line of therapy. Materials and Methods: All the patients with relapsed or refractory T-ALL aged from 0 to 18 years who received treatment with nelarabine as a part of the therapeutic element R6 were included in the study. For all patients a detailed immunological analysis of leukemia cells with discrimination of immunological variants TI, TII, TIII or TIV was performed. Patients administered with nelarabine as a first therapeutic element were referred to the first-line therapy group, other patients were referred to the second-line therapy group. Nelarabine was ad- ministered as intravenous infusion at a dose of 650 mg/m2, on days 1-5. Allogeneic hematopoietic stem cells transplantation (allo-HSCT) was considered for all patients. Results: From 2009 to 2017, 54 patients with refractory/relapsed T-ALL were treated with nelarabine. Five-year event-free survival (EFS) and overall survival (OS) was 28% for all patients, cumulative risk of relapse (CIR) was 27%. EFS was significantly higher in nelarabine first-line therapy group in comparison with second-line therapy group (34±8% vs 8±8%, p=0,05). In patients after allo-HSCT EFS, OS and CIR were 51±10%, 50±10% and 39,1±9,5% accordingly. The best results were achieved in patients with TI immunophenotype. No toxicity-related mortality as well as severe neurologic complications or discontinuation of therapy associated with use of nelarabine were reported. Conclusion: The use of nelarabine is an effective strategy for the treatment of relapsed and refractory T-ALL. The best treatment outcomes were obtained in patients with TI immunophenotype and in the first-line therapy group. Optimal dosage regimens can be established dur- ing controlled clinical trials. |
| فهرسة مساهمة: | Keywords: 9-β-D-arabinofuranosylguanine (ara-G); Moscow-Berlin protocol; T-ALL immunophenotyping; acute lymphoblastic leukemia; nelarabine; relapsed/refractory T cell acute lymphoblastic leukemia |
| المشرفين على المادة: | 0 (Antineoplastic Agents) 0 (Arabinonucleosides) 0 (Prodrugs) 60158CV180 (nelarabine) |
| تواريخ الأحداث: | Date Created: 20190201 Date Completed: 20190403 Latest Revision: 20190403 |
| رمز التحديث: | 20231215 |
| DOI: | 10.26442/terarkh201890738-50 |
| PMID: | 30701921 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 0040-3660 |
|---|---|
| DOI: | 10.26442/terarkh201890738-50 |